DFMO: Targeted risk reduction therapy for colorectal neoplasia

Christina M. Laukaitis, Eugene W. Gerner

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.

Original languageEnglish (US)
Pages (from-to)495-506
Number of pages12
JournalBest Practice and Research: Clinical Gastroenterology
Volume25
Issue number4-5
DOIs
StatePublished - Aug 2011

Keywords

  • Chemoprevention
  • Colorectal cancer
  • DFMO
  • Polyamines

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'DFMO: Targeted risk reduction therapy for colorectal neoplasia'. Together they form a unique fingerprint.

Cite this